Kottke-Marchant K - Search Results

1

Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy.

Kottke-Marchant K, Bahit MC, Granger CB, Zoldhelyi P, Ardissino D, Brooks L, Griffin JH, Potthoff RF, Van de Werf F, Califf RM, Topol EJ. Kottke-Marchant K, et al. Eur Heart J. 2002 Aug;23(15):1202-12. doi: 10.1053/euhj.2001.3074. Eur Heart J. 2002. PMID: 12127922 Clinical Trial.

2

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).

Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, Topol EJ. Lincoff AM, et al. Am Heart J. 2002 May;143(5):847-53. doi: 10.1067/mhj.2002.122173. Am Heart J. 2002. PMID: 12040347 Clinical Trial.

3

Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.

Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Nicolini FA, et al. Circulation. 1994 Apr;89(4):1802-9. doi: 10.1161/01.cir.89.4.1802. Circulation. 1994. PMID: 8149546

4

Heparin-induced thrombocytopenia.

Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Brieger DB, et al. J Am Coll Cardiol. 1998 Jun;31(7):1449-59. doi: 10.1016/s0735-1097(98)00134-x. J Am Coll Cardiol. 1998. PMID: 9626819 Free article. Review.

5

In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia.

Mak KH, Kottke-Marchant K, Brooks LM, Topol EJ. Mak KH, et al. Thromb Haemost. 1998 Dec;80(6):989-93. Thromb Haemost. 1998. PMID: 9869172

6

Coagulation markers and outcomes in acute coronary syndromes.

Ardissino D, Merlini PA, Eisenberg PR, Kottke-Marchant K, Crenshaw BS, Granger CB. Ardissino D, et al. Am Heart J. 1998 Oct;136(4 Pt 2 Su):S7-18. doi: 10.1053/hj.1998.v136.93436. Am Heart J. 1998. PMID: 9778084 Review. No abstract available.

7

Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis.

Nicolini FA, Lee P, Malycky JL, Lefkovits J, Kottke-Marchant K, Plow EF, Topol EJ. Nicolini FA, et al. Blood Coagul Fibrinolysis. 1996 Jan;7(1):39-48. doi: 10.1097/00001721-199601000-00005. Blood Coagul Fibrinolysis. 1996. PMID: 8845461

8

The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).

Kottke-Marchant K, Powers JB, Brooks L, Kundu S, Christie DJ. Kottke-Marchant K, et al. Clin Appl Thromb Hemost. 1999 Apr;5(2):122-30. doi: 10.1177/107602969900500209. Clin Appl Thromb Hemost. 1999. PMID: 10725993 Free article. Clinical Trial.

9

Profile and prevalence of aspirin resistance in patients with cardiovascular disease.

Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Gum PA, et al. Am J Cardiol. 2001 Aug 1;88(3):230-5. doi: 10.1016/s0002-9149(01)01631-9. Am J Cardiol. 2001. PMID: 11472699

10

First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions.

Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove CS, DeFranco AC, Ellis SG, Moliterno DJ, Raymond RE, Sutton JM, Topol EJ. Simpfendorfer C, et al. Circulation. 1997 Jul 1;96(1):76-81. doi: 10.1161/01.cir.96.1.76. Circulation. 1997. PMID: 9236420 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

143 results

Search Page